Cynbiose is thrilled with the accreditation of the BCF21 Biocluster dedicated to the development of innovative biotherapeutics and technologies in the field of emerging infectious diseases.

Cynbiose, a unique European preferred partner for the non-clinical development of candidates in the field of infectious diseases, is thrilled with the accreditation of the BCF21 Biocluster. The « Biocluster for Innovation in Infectious Diseases » is dedicated to the development of biotherapeutic and technological innovation in the field of emerging infectious diseases.  

Led by Lyonbiopôle, in association with BioMérieux, Sanofi, Boehringer-Ingelheim, the entire regional ecosystem involved in the fight against infectious diseases, Claude Bernard Lyon 1 University, Hospices Civils de Lyon, Institut Pasteur, Inserm-ANRS-MIE, APHP and University Paris Cité, with the support of the Auvergne-Rhône-Alpes Region and Lyon and Grenoble metropolitan areas, the BCF21 biocluster aims to support the development and commercialization of innovative and operational solutions to accelerate the fight against emerging infectious diseases and the emergence of antibiotic resistance, as part of a One Health approach. 

As part of this European-scale biocluster, Cynbiose will be committed to contributing to biotherapeutic innovation through its technological platforms, which have been developed along several axes: 

– The implementation of exploratory DMPK, toxicity and immunogenicity studies in a translational in vivo model, 

– Evaluation of candidates administered intranasally or by nebulization, such as antibodies, vaccines, antivirals and gene therapies, 

– The development of efficacy models using in vitro, rodent and non-rodent animal models, thanks to its know-how in infectiology and multiple partnerships with the VirNext platform, Bioaster and others to come. 

Cynbiose is making available, to the academic and industrial scientific community, its new AAALAC-accredited, versatile ABSL 1-3 facilities, one of a kind in Europe. Cynbiose offers a comprehensive preclinical offering, enhanced operational capacities and  secured supplies. 

Cynbiose is also strongly committed to two major research areas: 

– The fight against antibiotic resistance, as part of a research and development consortium along with Bioaster, PharmaLex and ICTA. 

– The microbiome: whether assessing the impact of the microbiome in infectious pathologies, the microbiome as a biomarker or the evaluation of drug candidates such as Medicinal Microbiome Products (particularly inhaled or aerosolized ones). 

Cynbiose is now the single European partner of choice for the non-clinical development of candidates in the field of infectious diseases. 

Contact us to discuss your projects and accelerate your innovations in this field!